<DOC>
	<DOCNO>NCT02401750</DOCNO>
	<brief_summary>This multicenter , randomize , double-blind , placebo-controlled , parallel-group , Phase 3 study evaluate efficacy safety administration multiple dose Oxycodone Hydrochloride plus Naltrexone Hydrochloride ( ) Oxycodone Hydrochloride plus Naltrexone Hydrochloride ( b ) patient undergone primary , unilateral , distal first metatarsal bunionectomy osteotomy internal fixation .</brief_summary>
	<brief_title>A Study Evaluate Safety Efficacy Following Dosing Oxycodone/Naltrexone Treatment Adults With Pain Following Bunionectomy Surgery</brief_title>
	<detailed_description>The study design evaluate safety efficacy oxycodone/naltrexone ( ) oxycodone/naltrexone ( b ) versus placebo . During blinded phase study ( inpatient portion ) dose regimen 1 capsule contain Oxycodone Hydrochloride plus Naltrexone Hydrochloride ( ) Oxycodone plus Naltrexone Hydrochloride ( b ) placebo take 4 6 ounce ( oz ) water every 6 hour ( q6h ) 48 hour follow first dose ( Multiple-dose Period ) in-house . Then open-label phase study ( outpatient portion ) dosing occur every 4 6 hour prn Oxycodone plus naltrexone . The active placebo study medication appear identical . Study subject acute postoperative pain moderate severe intensity follow unilateral bunionectomy surgery randomize surgery , stay study center duration 48-hour double-blind period dose 1 study medication . The study conduct follow 4 period : 1 ) pre-treatment period , 2 ) multiple-dose inpatient period ( double-blind ) , 3 ) multiple-dose outpatient period ( open-label ) , 4 ) End Study/Follow-up .</detailed_description>
	<mesh_term>Oxycodone</mesh_term>
	<mesh_term>Naltrexone</mesh_term>
	<criteria>1 . Complete inform consent process document sign informed consent form ( ICF ) . 2 . Be generally good health classify either PS1 PS2 American Society Anesthetists ( ASA ) Physical Status Classification System . 3 . Be male female , age 18 75 year , inclusively time screen . 4 . Be schedule primary , unilateral , distal , first metatarsal bunionectomy osteotomy internal fixation ( collateral procedure ) 5 . Female subject eligible follow apply : Not pregnant ( subject childbearing potential must negative serum betahuman chorionic gonadotropin ( BhCG ) pregnancy test screen negative urine pregnancy test surgery ) ; Not lactate ; Not plan become pregnant within duration study ; Surgically sterile ( bilateral tubal ligation hysterectomy ) , least two year postmenopausal , practice acceptable form birth control ( define use intrauterine device [ IUD ] , barrier method spermicide , condom , form hormonal contraceptive , partner vasectomy ( surgery least 6 week prior start surgery ) abstinence ) least 3 month prior screen visit agrees continue acceptable method contraception one week follow last dose ELI200 . 6 . Be willing complete pain assessment return clinic schedule . 7 . Subjects must experience postoperative pain ( Day 1 ) least moderate measure NRS score ≥ 4 010 NRS , less 9 hour discontinue nerve block . 1 . Have uncontrolled medical condition , serious intercurrent illness , clinically significant general health condition , extenuate circumstance may significantly decrease study compliance otherwise preclude participation study . 2 . Have clinically significant abnormal electrocardiogram ( ECG ) screening determine Investigator . 3 . Have type gastric bypass surgery gastric band . Have previous abdominal surgery within past year history abdominal adhesion , know suspect paralytic ileus . 4 . Have history medical condition surgical procedure would alter absorption , distribution , metabolism excretion oxycodone opioid include limit severe chronic diarrhea , chronic constipation , irritable bowel syndrome , bowel resection . 5 . Have history severe bronchial asthma , hypercarbia , hypoxia ( oxygen partial pressure [ PO2 ] &lt; 92 % ) respiratory condition , opinion investigator , make subject unsuitable study . Mild episodic asthma exercise induced asthma allow . 6 . Have , opinion investigator , clinically significant abnormality clinical laboratory value ( urinalysis , hematology chemistry ) screening . 7 . Have glycosylated hemoglobin ( 2c ) &gt; 7 % . 8 . Have Addison 's disease , benign prostatic hyperplasia , kidney disease condition outline Investigator 's Brochure Percocet Oxycontin Package Inserts contraindicate use . 9 . Have make donation ( standard donation amount ) blood blood product ( exception plasma note ) within 56 day prior Day 1 . 10 . Have make plasma donation within 7 day prior Day 1 . 11 . Have know allergy hypersensitivity opioid analgesic , naltrexone , anesthetic ( eg , propofol ) , acetaminophen , NSAIDs ( eg , ibuprofen naproxen , ketorolac ) excipients 12 . Have know allergy hypersensitivity ropivacaine , Mepivacaine , Lidocaine relate drug . 13 . Have history significant intolerance ( opinion investigator ) allergic hypersensitivity reaction opioid use . 14 . Not willing discontinue prohibit medication , within allotted time surgery throughout duration participation study . 15 . Have history substance ( recreational use ) alcohol ( 14 drink week ) abuse within 2 year screen . 16 . Have positive drug screen alcohol screen result . 17 . Use anticoagulant agent ( eg , Coumadin , heparin , etc ) 18 . Have positive test human immunodeficiency virus ( HIV ) , hepatitis B virus ( HBV ) , hepatitis C virus ( HCV ) screen visit . 19 . Have active malignancy type , diagnose cancer within 5 year prior screen ( exclude squamous basal cell carcinoma skin ) . 20 . Have dysphagia and/or swallow study medication whole . 21 . Use concurrent therapy could interfere evaluation efficacy safety parameter opinion investigator . ( eg , drug , investigator opinion , may exert significant analgesic property act synergistically oxycodone , morphine , ketorolac , acetaminophen ibuprofen ) . 22 . Have history seizure history serious head injury . 23 . Must member vulnerable population define Code Federal Regulations Title 45 , Part 46 , Section 46.111 ( b ) , include limited employee ( temporary , parttime , fulltime , etc . ) family member research staff conduct study , Sponsor , Clinical Research Organization . 24 . Have previously participate clinical trial use ( Oxycodone Hydrochloride Naltrexone Hydrochloride , 1.5 mg Oxycodone Hydrochloride , Naltrexone Hydrochloride 3.0 mg ) . 25 . Have history major mental illness opinion Investigator may affect ability subject participate study . Institutionalized subject eligible participation . 26 . Been expose investigational agent within 30 day five halflives ( whichever longer ) prior checkin Day 1 , Period 1 , schedule receive investigational device drug ( test product ) course study . Day 1 Exclusions : 1 . Have take follow drug within indicate time surgery : overthecounter prescription nonsteroidal antiinflammatory drug ( NSAIDs ) ( ibuprofen [ Advil® , Motrin® ] ) , acetaminophen , naproxen sodium ( Anaprox® , Aleve® ) within 24 hour ; daily dose 81 mg aspirin allow ( high dos must lower 81 mg day 72 hour prior surgery ) . naproxen sodium sustainedrelease ( Naprelan® ) within 72 hour C2 inhibitor ( piroxicam indomethacin ) within 5 day oxycodonecontaining drug analgesic drug contain opioids within past 14 day immediaterelease sedate antihistamine , tranquilizer , hypnotic within least 6 hour , longacting sustainedreleased form drug within least 7 day Day 1 Day 1 Exclusion : 1 . Have surgical complication ( Day 1 ) could compromise safety subject confound result trial reason , opinion investigator , make subject unsuitable participate .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>